Immunocore Holdings plc
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
IMCR$32.38+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of and
Condensed Consolidated Balance Sheets
(Unaudited) (In thousands, except share and per share data)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $512,245 | $467,709 |
| Marketable securities | 389,053 | 396,444 |
| Accounts receivable, net | 88,032 | 73,977 |
| Prepaid expenses and other current assets | 63,636 | 51,870 |
| Inventory, net | 7,467 | 6,742 |
| Total current assets | 1,060,433 | 996,742 |
| Property and equipment, net | 14,053 | 11,462 |
| Operating lease right of use assets, net | 36,272 | 38,783 |
| Other non-current assets | 18,481 | 20,282 |
| Total assets | $1,129,239 | $1,067,269 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $21,385 | $24,364 |
| Accrued expenses and other current liabilities | 205,894 | 219,744 |
| Deferred revenue, current | 573 | 583 |
| Operating lease liabilities, current | 1,767 | 2,006 |
| Total current liabilities | 229,619 | 246,697 |
| Accrued expenses, non-current | 41,600 | — |
| Deferred revenue, non-current | 4,344 | 4,858 |
| Operating lease liabilities, non-current | 39,220 | 41,556 |
| Interest-bearing loans and borrowings | 394,750 | 393,125 |
| Total liabilities | 709,533 | 686,236 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity | ||
| Ordinary shares (voting and non-voting), £0.002 par value, authority to allot up to a maximum nominal value of £149,303 and £149,633 shares as of September 30, 2026 and December 31, 2025, respectively, and 51,635,820 and 50,689,271 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively. | 139 | 136 |
| Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of September 30, 2026 and December 31, 2025. | 1 | 1 |
| Additional paid-in capital | 1,286,584 | 1,240,255 |
| Accumulated deficit | (833,334) | (831,275) |
| Accumulated other comprehensive loss | (33,684) | (28,084) |
| Total shareholders' equity | 419,706 | 381,033 |
| Total liabilities and shareholders' equity | $1,129,239 | $1,067,269 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.